<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347490</url>
  </required_header>
  <id_info>
    <org_study_id>ENOXA_L_00821</org_study_id>
    <nct_id>NCT00347490</nct_id>
  </id_info>
  <brief_title>HENOX: Enoxaparine in Hemodialysis</brief_title>
  <official_title>Efficacy and Safety in Hemodialysis With Enoxaparine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To assess clinical efficacy of single bolus anticoagulation with Enoxaparin in chronic&#xD;
      hemodialysis&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      To assess safety and tolerability by the number of spontaneously reported adverse events by&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fibrin / clot formation in dialyser and line grade in 10-point scale</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemodialysis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  End stage renal failure requiring maintenance hemodialysis at least twice a week&#xD;
&#xD;
          -  Has arterio-venous fistula or arterio-venous graft in upper extremities which can&#xD;
             apply to blood flow &gt; or = 250ml/min as a vascular access for hemodialysis.&#xD;
&#xD;
          -  Stable hemodialysis prescription at least 1 month before enrollment&#xD;
&#xD;
          -  UFH (Unfractionated Heparin) was prescribed as an anticoagulant in the previous&#xD;
             hemodialysis prescription&#xD;
&#xD;
          -  No sign of active infection .&#xD;
&#xD;
          -  Absence of recent cardiovascular complication such as myocardial infarction, DVT (Deep&#xD;
             Venous Thrombosis), arterial occlusion, pulmonary embolism, cerebrovascular disease in&#xD;
             previous 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or of childbearing age and not using medically&#xD;
             acceptable effective contraception&#xD;
&#xD;
          -  Patients with any evidence of an active bleeding disorder&#xD;
&#xD;
          -  Contraindication to anticoagulation:&#xD;
&#xD;
               -  Prior history of cerebral hemorrhage at any time&#xD;
&#xD;
               -  Coagulopathy (acquired or inherited)&#xD;
&#xD;
               -  Recent surgery&#xD;
&#xD;
               -  Major surgery such as neurosurgery within the past 3 months&#xD;
&#xD;
               -  Minor surgery such as intraocular surgery within 1 month.&#xD;
&#xD;
               -  Uncontrolled predialytic arterial hypertension (systolic BP &gt; 200 mmHg or&#xD;
                  diastolic BP &gt; 110 mmHg) at 2 successive readings&#xD;
&#xD;
               -  Impaired hemostasis i.e., known or suspected coagulopathy (acquired or&#xD;
                  inherited): baseline platelet count &lt;100,000/mm3 in patients without baseline&#xD;
                  diagnosis of active cancer and undergoing chemotherapy treatment (for patients&#xD;
                  with diagnosis of cancer and undergoing chemotherapy, baseline platelet count&#xD;
                  &gt;70,000/mm3); aPTT (activated Partial Thromboplastin Time) 1.5X the laboratory&#xD;
                  upper limit of normal; or international normalized ratio (INR) &gt;1.5&#xD;
&#xD;
          -  Indication for thrombolytic therapy such as ischemic heart disease, ischemic stroke.&#xD;
&#xD;
          -  Need for a curative treatment of anticoagulant therapy(DVT ,pulmonary embolism,&#xD;
             ischemic heart disease)&#xD;
&#xD;
          -  Patients treated with oral anticoagulant therapy within 72 hours prior to inclusion&#xD;
&#xD;
          -  Patients who have had spinal or epidural analgesia or lumbar puncture within the&#xD;
             preceding 24 hours&#xD;
&#xD;
          -  Abnormal liver enzyme and total bilirubin within 2 weeks (SGPT, SGOT, total bilirubin&#xD;
             above 2 times of Upper normal limit)&#xD;
&#xD;
          -  Known hypersensitivity to heparin or LMWH (Low Molecular Weight Heparin), or pork&#xD;
             derived products&#xD;
&#xD;
          -  History of documented episode of heparin or LMWH induced thrombocytopenia and/or&#xD;
             thrombosis.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sompob Paibulsirijit</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>January 22, 2008</last_update_submitted>
  <last_update_submitted_qc>January 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2008</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

